Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy OGSG1201
研究実績
検索結果:
すべて の研究実績
Stage II/III大腸癌根治切除後の補助化学療法中または治療後に再発したRAS野生型かつBRAF V600E変異型の早期再発大腸癌患者に対するエンコラフェニブ+ビニメチニブ+セツキシマブ療法の有効性と安全性を探索する第II相試験 (TRESBIEN/OGSG2101)
フッ化ピリミジン系薬剤とプラチナ系薬剤との併用療法に不応となった進行・再発食道癌に対するドセタキセル単独療法とパクリタキセル単独療法のランダム化比較第Ⅱ相試験(OGSG1201)
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease
The Phase II Study of Panitumumab in Chemotherapy- Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer OGSG 1602 Final Results
Neoadjuvant docetaxel, oxaliplatin and S‑1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902) protocol of a multi‑center, phase II study
Protocol of OGSG 1901 a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
A phase II study of S‑1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)